FrancophonIA/ELRC3.0 huggingface dataset:
English: At any time during or after your treatment, tell your doctor or nurse immediately if you: experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion.
Croatian: U bilo kojem trenutku tijekom ili nakon liječenja, odmah obavijestite svog liječnika ili medicinsku sestru ako: imate zamagljen vid, gubitak vida ili dvoslike, imate poteškoće s govorom, slabost u ruci ili nozi, primijetite promjenu u načinu hodanja ili imate probleme s ravnotežom, postojanu utrnulost, smanjen osjet ili gubitak osjeta, gubitak pamćenja ili smetenost.
English: Kyprolis is supplied in a glass vial as a white to off-white powder for solution for infusion, which is reconstituted (dissolved) before use.
Croatian: Kyprolis je dostupan u staklenoj bočici u obliku bijelog do prljavo bijelog praška za otopinu za infuziju, koji se rekonstituira (otapa) prije primjene.
English: Hydration, fluid and electrolyte monitoring
Croatian: Hidracija, praćenje tjelesnih tekućina i elektrolita
English: The overall incidence of venous thromboembolic events was higher in the Kyprolis arms of two phase 3 studies.
Croatian: Sveukupna incidencija događaja venske tromboembolije bila je viša u skupinama koje su primale Kyprolis u dva ispitivanja faze 3.
English: Kyprolis should be discontinued if PRES is suspected.
Croatian: Potrebno je prekinuti primjenu lijeka Kyprolis ako se sumnja na PRES.
English: In the event of an overdose, the patient should be monitored, specifically for the adverse reactions to Kyprolis listed in section 4.8.
Croatian: U slučaju predoziranja, bolesnika treba pratiti, posebno za nuspojave na lijek Kyprolis navedene u dijelu 4.8.
English: Cytochrome P450 mediated mechanisms played a minor role in overall carfilzomib metabolism.
Croatian: Mehanizmi posredovani citokromom P450 imali su neznatnu ulogu u sveukupnom metabolizmu karfilzomiba.
English: DO NOT SHAKE.
Croatian: NE TRESITE.
English: Carfilzomib is a P-glycoprotein (P-gp) but not a BCRP substrate.
Croatian: Karfilzomib je supstrat P-glikoproteina (P-gp), ali ne i BCRP-a.
English: Recommended actions and dose modifications are presented in table 3.
Croatian: Preporučeni postupci i prilagodba doze prikazani su u Tablici
English: Progressive Multifocal Leukoencephalopathy
Croatian: Progresivna multifokalna leukoencefalopatija
English: A total of 929 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy were enrolled and randomised (464 in the Kd arm; 465 in the Vd arm).
Croatian: Ukupno 929 bolesnika s recidivirajućim ili refraktornim multiplim mijelomom koji su prethodno primili 1 do 3 linije liječenja uključeno je u ispitivanje i randomizirano (464 u Kd skupini; 465 u Vd skupini).
English: • Inflammation of the nose and throat
Croatian: • Upala nosa i grla
English: However, Kyprolis treatment may also be stopped if you experience side effects that cannot be managed.
Croatian: Međutim, liječenje lijekom Kyprolis može se prekinuti i ako dođe do nuspojava koje se ne mogu liječiti.
English: Patients receiving carfilzomib should be monitored for any new or worsening neurologic, cognitive or behavioural signs and symptoms that may be suggestive of PML as part of the differential diagnosis of CNS disorders.
Croatian: Bolesnike koji primaju karfilzomib treba pratiti kako bi se uočila pojava novih ili pogoršavajućih neuroloških, kognitivnih ili bihevioralnih znakova i simptoma koji mogu upućivati na PML kao dio diferencijalne dijagnoze poremećaja središnjeg živčanog sustava.
English: a. Infusion time is 30 minutes and remains consistent throughout the regimen
Croatian: Trajanje infuzije je 30 minuta i ne mijenja se tijekom režima
English: Months from randomisation
Croatian: Mjeseci od randomizacije
English: Cycle 2 and all subsequent cycles
Croatian: Ciklus 2. i nadalje
English: In line with the labelling and risk minimisation activities proposed by Segec et al, inclusion of a warning on PML in section 4.4 of the SmPC is warranted.
Croatian: U skladu s označivanjem i aktivnostima minimizacije rizika koje su predložili Segec i sur., potrebno je uključiti upozorenje za PML u dijelu 4.4 sažetka opisa svojstava lijeka.
English: Similar proteasome inhibition by carfilzomib was achieved with 2 to 10 minute and 30 minute infusions at the 2 dose levels (20 and 36 mg/m2) at which it was tested.
Croatian: Slična inhibicija proteasoma karfilzomibom postignuta je primjenom 2 do 10-minutne i 30-minutne infuzije za 2 doze (20 i 36 mg/m2) pri kojima je lijek testiran.
English: • Absolute neutrophil count < 0.5 x 109/L (see section 4.4)
Croatian: • Apsolutni broj neutrofila < 0,5 x 109/l (vidjeti dio 4.4)
English: Dosing should be modified based on Kyprolis toxicity.
Croatian: Dozu treba prilagoditi s obzirom na toksičnost lijeka Kyprolis.
English: Frequency categories were determined from the crude incidence rate reported for each adverse reaction in a dataset of pooled clinical studies (n = 2,944).
Croatian: Kategorije učestalosti određene su prema gruboj stopi incidencije prijavljene za svaku nuspojavu u združenom skupu podataka iz kliničkih ispitivanja (n = 2944).
English: Recommended hydration includes both oral fluids (30 mL/kg/day for 48 hours before day 1 of cycle 1) and intravenous fluids (250 mL to 500 mL of appropriate intravenous fluid before each dose in cycle 1).
Croatian: Preporučena hidracija uključuje i peroralni unos tekućina (30 ml/kg/dan tijekom 48 sati prije 1. dana, 1. ciklusa) i intravenski unos tekućina (250 ml do 500 ml odgovarajuće intravenske tekućine prije svake doze u 1. ciklusu).
English: Carfilzomib is eliminated primarily via metabolism with subsequent excretion of its metabolites in urine.
Croatian: Karfilzomib se primarno eliminira metaboličkim putevima uz naknadnu ekskreciju razgradnih produkata u urinu.
English: Kyprolis can be administered directly by intravenous infusion or optionally administered in an intravenous bag.
Croatian: Kyprolis se može primijeniti direktno intravenski putem infuzije ili opcionalno, može se primijeniti i u vrećici za infuziju.
English: Kyprolis is a medicine that contains the active substance carfilzomib.
Croatian: Kyprolis je lijek koji sadrži djelatnu tvar karfilzomib.
English: Doses of ≥ 15 mg/m2 consistently induced an (≥ 80%) inhibition of the CT-L activity of the proteasome.
Croatian: Doze od ≥ 15 mg/m2 dosljedno su dovodile do (≥ 80%) inhibicije proteasomske CT-L aktivnosti.
English: Caution should be used in the concomitant administration of other agents that may increase the risk of thrombosis (e.g. erythropoietic agents or hormone replacement therapy).
Croatian: Potreban je oprez prilikom istodobne primjene drugih lijekova koji mogu povećati rizik od tromboze (npr. lijekovi koji stimuliraju eritropoezu ili hormonska nadomjesna terapija).
English: While taking Kyprolis, and for 30 days after stopping treatment you should use a suitable method of contraception to ensure you do not become pregnant.
Croatian: Tijekom liječenja i 30 dana nakon završetka primjene lijeka Kyprolis trebate primjenjivati odgovarajuću metodu kontracepcije kako biste bili sigurni da nećete zatrudnjeti.
English: A 30 minute infusion resulted in a similar half-life and AUC, but 2- to 3-fold lower Cmax compared to that observed with a 2 to 10 minute infusion of the same dose.
Croatian: Infuzija u trajanju od 30 minuta rezultirala je sličnim vrijednostima poluvijeka i AUC, ali 2 do 3 puta nižom vrijednosti Cmax u usporedbi s onom opaženom za 2- do 10-minutnu infuziju iste doze.
English: Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects.
Croatian: Talidomid je djelatna tvar poznato teratogena u ljudi, koja uzrokuje teške urođene mane opasne po život.
English: If foaming occurs, allow the solution to settle in the vial until foaming subsides (approximately 5 minutes) and the solution is clear.
Croatian: Ako se stvori pjena, pustite otopinu da se slegne u bočici do nestanka pjene (oko 5 minuta) i dok otopina ne postane bistra.
English: Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that selectively and irreversibly binds to the N terminal threonine containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome, and displays little to no activity against other protease classes.
Croatian: Karfilzomib je tetrapeptidni epoksiketonski inhibitor proteasoma koji se selektivno i ireverzibilno veže na aktivno mjesto 20S proteasoma koje sadrži N-terminalni treonin, središnju proteolitičku česticu unutar 26S proteasoma, dok spram drugih razreda proteaza pokazuje nikakvu ili vrlo malu aktivnost.
English: • Febrile neutropenia
Croatian: • Febrilna neutropenija
English: It is not known if Kyprolis passes into breast milk in humans.
Croatian: Nije poznato prelazi li lijek Kyprolis u majčino mlijeko u ljudi.
English: Caution should be observed when carfilzomib is combined with substrates of P-gp (e.g. digoxin, colchicine).
Croatian: Potreban je oprez kada se karfilzomib primjenjuje u kombinaciji sa supstratima P-gp-a (npr. digoksin, kolhicin).
English: Kyprolis vials contain no antimicrobial preservatives and are intended for single use only.
Croatian: Bočice lijeka Kyprolis ne sadrže antimikrobne konzervanse i namijenjene su isključivo za jednokratnu primjenu.
English: The pharmacokinetics of carfilzomib has not been studied in patients with severe hepatic impairment (bilirubin > 3 x ULN and any AST).
Croatian: Farmakokinetika karfilzomiba nije ispitivana u bolesnika s teškim oštećenjem jetre (bilirubin > 3 x GGN i bilo koja vrijednost AST).
English: Following intravenous administration of doses ≥ 15 mg/m2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on day 1 of cycle 1.
Croatian: Nakon intravenske primjene doza od ≥ 15 mg/m2, karfilzomib se brzo eliminirao iz sistemske cirkulacije, s poluživotom od ≤ 1 sat na 1. dan 1. ciklusa.
English: Patients enrolled to study PX-171-011 were more heavily pre-treated with lower organ and marrow function as compared to those enrolled in study PX-171-009.
Croatian: Bolesnici koji su bili uključeni u ispitivanje PX-171-011 bili su prethodno pod jačim liječenjem i imali su slabiju funkciju organa i koštane srži u usporedbi s bolesnicima uključenima u ispitivanje PX-171-009.
English: The intravenous administration line should be flushed with normal sodium chloride solution or 5% glucose solution for injection immediately before and after Kyprolis administration.
Croatian: Cjevčica za intravensku primjenu treba se isprati fiziološkom otopinom natrijevog klorida ili 5%-tnom otopinom glukoze za injekciju neposredno prije i nakon primjene lijeka Kyprolis.
English: The predominant metabolites measured in human plasma and urine, and generated in vitro by human hepatocytes, were peptide fragments and the diol of carfilzomib, suggesting that peptidase cleavage and epoxide hydrolysis were the principal pathways of metabolism.
Croatian: Prevladavajući razgradni produkti mjereni u humanoj plazmi i urinu te nastali in vitro putem aktivnosti ljudskih hepatocita bili su peptidni fragmenti i diol karfilzomiba, što upućuje na to da su glavni putevi metabolizma cijepanje peptidazama i hidroliza epoksida.
English: This means that Kyprolis will be given to you on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
Croatian: To znači da će se Kyprolis u Vas primjenjivati 1., 2., 8., 9., 15. i 16. dana u svakom ciklusu od 28 dana.
English: The metabolites have no known biologic activity.
Croatian: Razgradni produkti nemaju nikakvu poznatu biološku aktivnost.
English: Hypertension including hypertensive crises
Croatian: Hipertenzija, uključujući hipertenzivnu krizu
English: If your partner becomes pregnant whilst you are taking Kyprolis or within 90 days after stopping treatment, notify your doctor or nurse immediately.
Croatian: Ako Vaša partnerica zatrudni dok Vi uzimate Kyprolis ili unutar 90 dana nakon završetka Vašeg liječenja lijekom Kyprolis, odmah obavijestite Vašeg liječnika ili medicinsku sestru.
English: While taking Kyprolis and for 90 days after stopping treatment, you should use a condom even if your partner is pregnant.
Croatian: Tijekom liječenja i 90 dana nakon završetka primjene lijeka Kyprolis trebate koristiti kondom, čak i ako je Vaša partnerica trudna.
English: No effects on reproductive tissues were noted during 28-day repeat-dose rat and monkey toxicity studies or in 6-month rat and 9-month monkey chronic toxicity studies.
Croatian: Nije zapažen učinak na reproduktivna tkiva tijekom ispitivanja toksičnosti uz opetovano doziranje u štakora i majmuna kroz period od 28 dana ili u ispitivanjima kronične toksičnosti u štakora u trajanju od 6 te u majmuna u trajanju od 9 mjeseci.
English: If the diagnosis of TTP/HUS is excluded, Kyprolis can be restarted.
Croatian: Ako se isključi dijagnoza TTP-a/HUS-a, može se ponovo započeti s primjenom lijeka Kyprolis.
English: PX-171-003A1 was a single-arm phase 2 study (N = 266; exposure to ≥ 2 prior therapies required), which met its primary efficacy endpoint of IRC-assessed ORR (22.9%).
Croatian: Ispitivanje PX-171-003A1 bilo je ispitivanje faze 2 s jednom skupinom (N = 266; potrebna izloženost do ≥ 2 prethodna liječenja), koje je postiglo svoj primarni ishod djelotvornosti IRC-procijenjenog ORR-a (22,9%).
English: The majority of dyspnoea adverse reactions were non-serious (< 5% of subjects had grade ≥ 3 events), resolved, rarely resulted in treatment discontinuation, and had an onset early in the course of study (< 3 cycles).
Croatian: Većina nuspojava dispneje nije bila ozbiljna (< 5% ispitanika imalo je događaj 3. ili višeg stupnja), povukle su se i rijetko su rezultirale prekidom liječenja, a javljale su se rano u tijeku ispitivanja (< 3 ciklusa).
English: Lenalidomide is expected to be harmful to the unborn child. As Kyprolis is given in combination with lenalidomide, you must follow the Pregnancy Prevention Programme (see package leaflet for lenalidomide for information on pregnancy prevention and discuss with your doctor, pharmacist or nurse).
Croatian: S obzirom da se Kyprolis primjenjuje u kombinaciji s lenalidomidom, morate se pridržavati Programa prevencije trudnoće (za informacije o prevenciji trudnoće pogledajte Uputu o lijeku za lenalidomid i raspravite sa svojim liječnikom, ljekarnikom ili medicinskom sestrom).
English: Treatment with Kyprolis has not been evaluated in pregnant women.
Croatian: Liječenje lijekom Kyprolis nije procijenjeno u trudnica.
English: Following repeated doses of Kyprolis at 15 and 20 mg/m2, systemic exposure (AUC) and half-life were similar on days 1 and 15 or 16 of cycle 1, suggesting there was no systemic carfilzomib accumulation.
Croatian: Nakon opetovane primjene lijeka Kyprolis u dozama od 15 i 20 mg/m2, sistemska izloženost (AUC) i poluživot su bili slični na dane 1 i 15 ili 16 u 1. ciklusu, što upućuje da nije bilo sistemske akumulacije karfilzomiba.
English: However, it is unknown whether carfilzomib is an inducer of CYP1A2, 2C8, 2C9, 2C19 and 2B6 at therapeutic concentrations.
Croatian: Međutim, nije poznato inducira li karfilzomib pri terapijskim koncentracijama CYP1A2, 2C8, 2C9, 2C19 i 2B6.
English: • Viral infection
Croatian: • Virusna infekcija
English: However, given that Kyprolis is administrated intravenously and is extensively metabolised, the pharmacokinetic profile of carfilzomib is unlikely to be affected by P-gp or BCRP inhibitors or inducers.
Croatian: Međutim, s obzirom da se Kyprolis primjenjuje intravenski i opsežno se metabolizira, nije vjerojatno da će na farmakokinetički profil karfilzomiba utjecati inhibitori ili induktori P-gp-a ili BCRP-a.
English: Effective measures to avoid pregnancy should be taken (see section 4.6, and refer also to the current lenalidomide summary of product characteristics), an alternative method of effective contraception should be used if the patient is using oral contraceptives.
Croatian: Trebaju se poduzeti učinkovite mjere za prevenciju trudnoće (vidjeti dio 4.6 i važeći sažetak opisa svojstava lijeka za lenalidomid), a u slučaju da bolesnica uzima oralne kontraceptive trebaju se primijeniti alternativne učinkovite metode kontracepcije.
English: • Low blood pressure (hypotension)
Croatian: • Nizak krvni tlak (hipotenzija)
English: Stop Kyprolis until TLS is resolved (see section 4.2).
Croatian: Prekinite primjenu lijeka Kyprolis dok se TLS ne razriješi (vidjeti dio 4.2).
English: Dehydration Hyperkalaemia Hypomagnesaemia Hyponatraemia Hypercalcaemia Hypocalcaemia Hypophosphataemia Hyperuricaemia Hypoalbuminaemia
Croatian: Dehidracija Hiperkalijemija Hipomagnezijemija Hiponatremija Hiperkalcemija Hipokalcemija Hipofosfatemija Hiperuricemija Hipoalbuminemija
English: The reconstituted solution is a clear, colourless or slightly yellow solution.
Croatian: Rekonstituirana otopina je bistra, bezbojna ili žućkasta otopina.
English: A clinical trial using oral midazolam as a CYP3A probe conducted with carfilzomib at a dose of 27 mg/m2 (2-10 minute infusion) demonstrated that the pharmacokinetics of midazolam were unaffected by concomitant carfilzomib administration, indicating that carfilzomib is not expected to inhibit the metabolism of CYP3A4/5 substrates and is not a CYP3A4 inducer in human subjects.
Croatian: Kliničko ispitivanje u kojem je kao CYP3A proba korišten oralno primijenjen midazolam, provedeno s karfilzomibom u dozi od 27 mg/m2 (infuzija u trajanju od 2 do 10 minuta), pokazalo je da na farmakokinetiku midazolama ne utječe istodobna primjena karfilzomiba, ukazujući da se ne očekuje da će karfilzomib inhibirati metabolizam CYP3A4/5 supstrata te da nije induktor CYP3A4 u ljudi.
English: Fertility studies with carfilzomib have not been conducted.
Croatian: Nisu provedena ispitivanja plodnosti s karfilzomibom.
English: The pharmacokinetics of Kyprolis has not been evaluated in patients with severe hepatic impairment.
Croatian: Farmakokinetika lijeka Kyprolis nije procijenjena u bolesnika s teškim oštećenjem jetre.
English: These included 1 well-documented serious case of hepatitis B reactivation with a likely association with carfilzomib and no substantial confounders, and 1 case of hepatitis B reactivation suggestive of a causal association which developed with the addition of carfilzomib to an ongoing regimen of lenalidomide plus dexamethasone, as well as 20 other serious cases which had, at minimum, a plausible temporal association with carfilzomib.
Croatian: Oni uključuju 1 dobro dokumentirani ozbiljan slučaj reaktivacije hepatitisa B koji je vjerojatno povezan s karfilzomibom i bez značajnih zbunjujućih čimbenika te 1 slučaj reaktivacije hepatitisa B koji ukazuje na uzročnu povezanost gdje se reaktivacija razvila dodavanjem karfilzomiba u režim lenalidomida i deksametazona u tijeku, kao i 20 drugih ozbiljnih slučajeva koji su imali barem moguću vremensku povezanost s karfilzomibom.
English: There is biological plausibility for carfilzomib induced PML (lymphopenia and opportunistic infections are expected ADRs).
Croatian: Postoji biološka vjerojatnost za PML (progresivna multifokalna leukoencefalopatija) izazvan karfilzomibom (očekivane nuspojave su limfopenija i oportunističke infekcije).
English: Carfilzomib administered to pregnant rats during the period of organogenesis was not teratogenic at doses up to 2 mg/kg/day, which is approximately half the recommended dose in humans of 27 mg/m2 based on BSA.
Croatian: Karfilzomib primijenjen u gravidnih ženki štakora tijekom perioda organogeneze nije bio teratogen pri dozama do 2 mg/kg/dan, što je otprilike polovica preporučene doze od 27 mg/m2 u ljudi, koja se temelji na BSA.
English: On the basis of the scientific conclusions for carfilzomib the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing carfilzomib is unchanged subject to the proposed changes to the product information.
Croatian: Na temelju znanstvenih zaključaka za karfilzomib, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) karfilzomib nepromijenjen, uz predložene izmjene informacija o lijeku.
English: Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin-like (CT-L) activity when measured in blood 1 hour after the first dose.
Croatian: Intravenska primjena karfilzomiba rezultirala je supresijom proteasomske aktivnosti nalik kimotripsinu (CT-L, od eng. chymotrypsin-like), mjereno u krvi jedan sat nakon prve doze.
English: • Feeling too hot
Croatian: • Osjećaj prekomjerne vrućine
English: As lenalidomide may be used in combination with Kyprolis, particular attention to the lenalidomide pregnancy testing and prevention requirements is needed (see section 4.6).
Croatian: S obzirom da se lenalidomid može primjenjivati u kombinaciji s lijekom Kyprolis, potrebno je posebnu pozornost obratiti na zahtjeve za testiranje na trudnoću i prevenciju trudnoće kod primjene lenalidomida. (vidjeti dio 4.6).
English: Hepatitis B Virus (HBV) Reactivation
Croatian: Reaktivacija virusa hepatitisa B (HBV)
English: The dose will be calculated based on your height and weight (body surface area).
Croatian: Vaše visine i tjelesne težine (površine tijela).
English: Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, haemoptysis, arm or leg swelling or pain.
Croatian: Bolesnike je potrebno uputiti da potraže liječničku pomoć ako se razviju simptomi poput nedostatka zraka, boli u prsištu, hemoptize te boli ili oticanja ruku ili nogu.
English: • Lung problems, including a history of shortness of breath at rest or with activity (dyspnoea)
Croatian: • Problemi s plućima, uključujući povijest nedostatka zraka u mirovanju ili tijekom aktivnosti (dispneja)
English: Powder vial (unopened)
Croatian: Bočica s praškom (neotvorena)
English: Tell your doctor right away if you get worsening tiredness, or yellowing of your skin or white part of your eyes.
Croatian: Odmah obavijestite svog liječnika ako vam se pojača umor ili u slučaju pojave žute boje kože ili bjeloočnica.
English: Patients with known risk factors for thromboembolism - including prior thrombosis - should be closely monitored.
Croatian: Bolesnike s poznatim čimbenicima rizika za tromboemboliju - uključujući prethodnu trombozupotrebno je pomno pratiti.
English: The reconstituted product should be a clear, colourless to slightly yellow solution and should not be administered if any discolouration or particulate matter is observed.
Croatian: Rekonstituirani lijek treba biti bistra, bezbojna do žućkasta otopina i ne smije se primjenjivati ako se opazi bilo kakva promjena boje ili prisutnost čestica.
English: 95% CI of ORR 1-sided p-valueb
Croatian: 95% CI od ORR Jednostrana p-vrijednostb
English: PRES, formerly termed reversible posterior leukoencephalopathy syndrome (RPLS), is a rare, neurological disorder, which can present with seizure, headache, lethargy, confusion, blindness, altered consciousness, and other visual and neurological disturbances, along with hypertension, and the diagnosis is confirmed by neuro-radiological imaging.
Croatian: PRES, ranije zvan i sindrom posteriorne reverzibilne leukoencefalopatije (RPLS, od engl. reversible posterior leukoencephalopathy syndrome), rijedak je neurološki poremećaj u kojem se mogu javiti napadaji, glavobolja, letargija, konfuzija, sljepoća, poremećaji svijesti i drugi poremećaji vida i neurološki poremećaji, zajedno s hipertenzijom, a dijagnoza se potvrđuje slikovnim neuro-radiološkim oslikavanjem.
English: Proportion surviving without progression
Croatian: Udio preživljenja bez progresije bolesti
English: • Stop dose and continue monitoring renal function (serum creatinine or creatinine clearance) Kyprolis should be resumed when renal function has recovered to within 25% of baseline; consider resuming at 1 dose level reductiona
Croatian: • Prekinite liječenje i nastavite pratiti bubrežnu funkciju (kreatinin u serumu ili klirens kreatinina) Nastavite liječenje lijekom Kyprolis kada se bubrežna funkcija oporavi na 25% početne vrijednosti; razmotrite nastavak liječenja smanjenjem doze za 1 razinua